Neurocrine Biosciences
Financial ratios & Valuation

Forward Multiples (2025 – 2028)

2025202620272028
Price/Earnings ratio
20.9415.2212.5310.21
Price/Sales ratio
4.934.233.763.31
Earnings per Share (EPS)
$6.34$8.72$10.59$13.00

Historical Multiples (2014 – 2023)

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 TTM Median
Valuation Ratios
Price/Earnings ratio
-27.51-53.75-23.74-47.89322.69266.1821.9089.9274.0651.5564.33266.18
Price/Sales ratio
N/A241.78223.3242.2315.0912.498.537.107.686.826.6712.49
Price/Book Value ratio
7.9811.2610.6318.3414.1715.467.925.866.705.765.8215.46
Price/Cash Flow ratio
-35.34-125.79-31.54-72.3767.2064.7739.0531.4133.7133.0129.2864.77
Price/Free Cash Flow ratio
-34.17-119.70-30.37-67.4188.9971.7341.0034.5635.4335.5930.7871.73
Price/Earnings Growth ratio
-1.58-1.81-0.4278.06-2.843.250.02-1.141.060.870.90-2.84
Dividend Yield
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Profitability Indicator Ratios
Gross Profit Margin
N/A-70.97%-139.33%99.22%98.91%99.06%99.03%98.73%98.44%97.89%98.44%99.06%
Operating Profit Margin
N/A-476.51%-982.48%-81.27%8.17%27.80%30.49%17.37%16.72%13.29%16.72%8.17%
Pretax Profit Margin
N/A-449.84%-940.6%-88.19%4.84%5.90%10.20%8.94%14.36%17.59%14.36%4.84%
Net Profit Margin
N/A-449.84%-940.6%-88.19%4.67%4.69%38.94%7.90%10.37%13.23%10.37%4.67%
Effective Tax Rate
7.72%7.05%5.47%-11.99%3.34%20.43%-281.72%11.63%27.77%24.81%27.77%3.34%
Return on Assets
-24.91%-18.73%-38.64%-17.43%2.12%2.83%23.47%4.32%6.52%7.67%6.52%2.12%
Return On Equity
-29.00%-20.95%-44.80%-38.30%4.39%5.80%36.16%6.52%9.04%11.18%10.18%4.39%
Return on Capital Employed
-28.32%-20.97%-44.03%-17.21%4.07%29.58%20.59%10.77%13.59%9.66%13.59%4.07%
Liquidity Ratios
Current Ratio
12.6514.9310.2010.198.361.475.44N/AN/AN/A2.701.47
Quick Ratio
12.6514.9310.2010.768.231.435.293.832.632.39N/A1.43
Cash ratio
1.972.882.734.671.600.194.291.380.480.38N/A0.19
Days of Sales Outstanding
N/AN/AN/A70.2945.4958.6254.8259.7385.8184.96N/A58.62
Days of Inventory outstanding
N/AN/AN/A-9.06K811.07852.711.01K778.49552.21352.12N/A852.71
Operating Cycle
N/AN/AN/A-8.98K856.56911.341.06K838.22638.03437.09N/A911.34
Days of Payables Outstanding
6.2327.6551.691.64K1.03K2.04K1.42K1.31K1.05K1.00KN/A2.04K
Cash Conversion Cycle
N/A-27.65-51.69-10.63K-173.77-1.13K-357.15-476.28-420.78-564.12N/A-173.77
Debt Ratios
Debt Ratio
N/AN/AN/A0.450.390.310.180.160.070.050.270.31
Debt Equity Ratio
N/AN/AN/A0.990.800.640.280.240.090.070.380.64
Long-term Debt to Capitalization
N/AN/AN/A0.490.44N/A0.220.19N/AN/A0.05N/A
Total Debt to Capitalization
N/AN/AN/A0.490.440.390.220.190.090.070.130.39
Interest Coverage Ratio
N/AN/AN/A-6.721.207.089.98N/AN/AN/A35.071.20
Cash Flow to Debt Ratio
N/AN/AN/A-0.250.260.370.710.762.002.291.290.26
Company Equity Multiplier
1.161.111.152.192.062.051.541.501.381.451.382.05
Cash Flow Ratios
Operating Cash Flow / Sales Ratio
N/A-1.92-7.07-0.580.220.190.210.220.220.200.220.22
Free Cash Flow / Operating Cash Flow Ratio
1.031.051.031.070.750.900.950.900.950.920.950.75
Cash Flow Coverage Ratio
N/AN/AN/A-0.250.260.370.710.762.002.291.290.26
Short Term Coverage Ratio
N/AN/AN/AN/AN/A0.37N/AN/A2.002.292.000.37
Dividend Payout Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A